Ilya Pharma has been invited to present its ILP100 accelerated wound healing therapy at the US Military Health System Research Symposium (MHSRS) 2021, to be held August 23-26 at the Gaylord Convention Center in Florida. Results for the company’s first in human trial were released earlier this year and it has recently received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds.
During its Cellular Therapeutics for Treatment of Shock and Trauma session, Ilya will report on how this new-in-class drug candidate of engineered Limosilactobacillus reuteri bacteria produces and releases the key human chemokine CXCL12 at the actual wound site. After delivery, ILP100 enhances the healing properties of immune cells in the wound.
Ilya has now been granted permission in Sweden to conduct a Phase II trial commencing in the third quarter of 2021.
Image credit: Diana Polekhina
